---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134064"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:41:36.610285+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA accepts IND for Gemini Phase 1b CKD study; REVB raises ~$4.1M from warrant exercises

## Summary
- FDA accepted IND for Gemini (trained immunity) for Phase 1b study in up to 40 CKD patients; primary endpoint safety/tolerability.
- Existing Class E warrants exercised at $1.00/share for ~$4.1M gross proceeds; new Class F and G warrants issued as inducement.
- Proceeds to fund clinical trials for GEM-AKI, GEM-CKD, GEM-PSI and working capital.
- New Class F warrants (2yr, $1.00) and Class G warrants (5yr, $1.00) subject to stockholder approval; include cashless exercise provisions.

## SEC filing metadata
- accession: 0000950170-24-134064
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024134064/0000950170-24-134064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024134064/revb-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134064
- JSON: https://secwatch.observer/filing/0000950170-24-134064.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.